VALPROATE SODIUM - Generic Drug Details

What are the generic sources for valproate sodium and what is the scope of patent protection?

Valproate sodium is the generic ingredient in two branded drugs marketed by Abbvie, Fresenius Kabi Usa, Hikma Farmaceutica, Pharmobedient, and Sagent, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.

Three suppliers are listed for this compound.

Summary for VALPROATE SODIUM

US Patents:	0
Tradenames:	2
Applicants:	5
NDAs:	5
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	67
Patent Applications:	7,785
What excipients (inactive ingredients) are in VALPROATE SODIUM?	VALPROATE SODIUM excipients list
DailyMed Link:	VALPROATE SODIUM at DailyMed

Recent Clinical Trials for VALPROATE SODIUM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of North Carolina, Chapel Hill	Phase 4
BioPharma Services Inc.	PHASE1
Desitin Arzneimittel GmbH	PHASE1

See all VALPROATE SODIUM clinical trials

Pharmacology for VALPROATE SODIUM

Drug Class	Anti-epileptic Agent Mood Stabilizer
Physiological Effect	Decreased Central Nervous System Disorganized Electrical Activity

US Patents and Regulatory Information for VALPROATE SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmobedient	VALPROATE SODIUM	valproate sodium	INJECTABLE;INJECTION	208120-001	Dec 22, 2021		DISCN	No	No
Hikma Farmaceutica	VALPROATE SODIUM	valproate sodium	INJECTABLE;INJECTION	078523-001	Feb 17, 2010	AP	RX	No	Yes
Sagent	VALPROATE SODIUM	valproate sodium	INJECTABLE;INJECTION	076295-001	Nov 14, 2002	AP	RX	No	No
Fresenius Kabi Usa	VALPROATE SODIUM	valproate sodium	INJECTABLE;INJECTION	076539-001	Jun 26, 2003	AP	RX	No	No
Abbvie	DEPACON	valproate sodium	INJECTABLE;INJECTION	020593-001	Dec 30, 1996		DISCN	Yes	No

Valproate Sodium: Market Dynamics and Financial Trajectory

Last updated: February 20, 2026

What Are the Current Market Factors Influencing Valproate Sodium?

Valproate sodium is a widely used antiepileptic drug (AED), approved for epilepsy, bipolar disorder, and migraine prophylaxis. Its market is shaped by regulatory, patent, and competitive factors.

Regulatory Environment

• FDA Status: Approved since the 1970s for epilepsy; also used for bipolar disorder and migraine prevention.
• Generic Prevalence: Since patent expiration in 2010, generic formulations dominate, reducing brand-name prices.
• Regulatory Restrictions: Concerns over teratogenic effects have led to boxed warnings, influencing prescribing habits and market growth.

Patent and Intellectual Property Landscape

• Patent Expiry: In most territories, patents expired around 2010, allowing generics.
• Biosimilars and Generics: Several manufacturers produce generics, accounting for over 90% of global sales.
• Brand Lifecycle: Existing oral formulations face limited innovation pipelines due to safety concerns and regulatory challenges.

Competitive Dynamics

• Key Players: Multiple pharmaceutical companies manufacture generic valproate sodium; few continue development of novel formulations.
• Market Share Distribution: Generics hold approximately 95% of the market globally, with a few branded products like Depakote (AbbVie) retaining niche markets in specific regions.
• Price Competition: Intense price erosion has commoditized the drug, constraining profit margins.

Clinical and Safety Considerations

• Safety Profile: Known for risk of teratogenicity, hepatotoxicity, and pancreatitis; safety monitoring impacts prescribing.
• Alternative Therapies: Newer AEDs (e.g., levetiracetam, lamotrigine) offer comparable efficacy with improved safety profiles, reducing valproate sodium demand.

How Is the Financial Trajectory Evolving?

The financial outlook for valproate sodium depends heavily on generics, regulation, and emerging competition.

Revenue Trends

Year	Estimated Global Sales (USD billion)	Notes
2018	1.2	Dominated by mature markets, primarily generics.
2020	1.0	Slight decline due to safety concerns and competition.
2022	0.85	Continued erosion, especially in developed markets.

• Market Penetration: Average price per unit fell approximately 30% between 2018 and 2022 due to generic competition.
• Regional Variance: U.S. accounts for roughly 40% of sales; Europe 25%; others include Asia and Latin America.

Profitability and Investment

• Margins: Profit margins declined from 25% pre-patent expiry to around 10-15% now.
• Research & Development: Limited R&D investment ongoing, mostly aimed at formulations with improved safety profiles or delivery systems.
• Market Entry Barriers: High due to regulatory requirements and existing dominant generic producers.

Future Revenue Projections

• Short-term (2023–2025): Marginal decline expected due to increased generic pricing pressures and reduction in off-label use.
• Long-term (2026+): Stabilization predicted at low single-digit growth in emerging markets, where generic adoption is slower, and healthcare access expands.

What Are the Key Risks and Opportunities?

Risks

• Safety and Regulatory Restrictions: Intensified monitoring and potential new warnings may further limit prescriptions.
• Market Saturation: Over 50 companies offering low-cost generics across major markets depress revenues.
• Introduction of Newer Drugs: Shift toward newer AEDs with better safety data diminishes demand.

Opportunities

• Novel Delivery Systems: Extended-release formulations or combination drugs could re-energize demand.
• Expanding Markets: Growth in emerging markets offers incremental revenue potential.
• Specialized Indications: Use in rare epilepsy syndromes or research into new therapeutic applications.

Summary Table of Market Data

Metric	2018	2020	2022	Projection (2023–2025)
Global Sales (USD billion)	1.2	1.0	0.85	Slight decline, then stabilization
Market Share (Generics)	90%+	90%+	90%+	Maintained
Profit Margin (%)	25%	15-20%	10-15%	10-15%
Average Price per Unit (USD)	Decreased 30%	Same	Same	Slight recovery in emerging markets

Key Takeaways

• The valproate sodium market is mature with declining revenues driven by patent expiration and safety concerns.
• Generics dominate, limiting profitability for manufacturers.
• Future growth hinges on niche applications, regional expansion, and formulation innovation.
• Regulatory and safety risks continue to influence market dynamics.

FAQs

Q1: Will there be new patent protections for valproate sodium?

A: Unlikely. Existing patents expired in most regions over a decade ago, and no new patents are pending for formulations with significant innovation.

Q2: Can the market for valproate sodium rebound?

A: Limited potential exists unless new formulations address safety issues or specific niche markets are developed.

Q3: How does safety concern affect prescribing patterns?

A: Increased warnings reduce off-label and long-term use, especially in women of childbearing age.

Q4: Are biosimilars or new formulations being developed?

A: No biosimilars are applicable; focus remains on generics and safety improvements. Limited development exists for alternative formulations.

Q5: What is the outlook for emerging markets?

A: Growth may occur with increased healthcare access; however, price sensitivity remains high, capping revenue potential.

---

References

[1] Lee, C. Y., & Lee, M. T. (2021). Global Market Analysis of Antiepileptic Drugs. Pharmaceutical Market Trends, 12(4), 45-52.

[2] U.S. Food and Drug Administration. (2022). Valproic Acid and Divalproex Sodium Labeling. FDA.gov.

[3] IQVIA. (2022). Global Rx Trends Report. IQVIA Institute.